The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice

To evaluate the effectiveness of benralizumab in patients with the eosinophilic phenotype of severe asthma in real clinical practice after a year of therapy.

Methods. During Benralizumab therapy, 13 patients with severe eosinophilic asthma (average age – 55.44 ± 7.18 years old) were examined twice: before the treatment and after 1 year of benralizumab therapy. The assessment included collection of complaints, medical history, current therapy, Asthma Control Questionnaire (ACQ-5) test, absolute blood count of eosinophils, spirometry.

Results. All patients initially had pronounced eosinophilia of 577.5 ± 356.4 cells/μl. After 1 year of using benralizumab, the eosinophil count decreased by 96.15%. During therapy, the ACQ-5 index decreased from 1.63 ± 0.62 to 0.73 ± 0.41 in the study patients, which corresponded to the achievement of asthma control. The forced expiratory volume in 1 second (FEV1) increased by 23 %. The number of exacerbations decreased by 58.09%. 12 (92.31%) patients were on oral corticosteroids (OCS) (10 ± 2.17 mg of prednisolone daily) before benralizumab therapy. All subjects noted a decrease in night and day symptoms over time and were able to reduce the use of OCS. 5 (38.46%) patients achieved complete elimination of daily OCS use, 7 (53.84%) patients were able to reduce their daily OCS dose.

Conclusion. Benralizumab therapy as an add-on maintenance treatment in patients with eosinophilic phenotype of severe asthma contributes to a significant decrease in peripheral blood eosinophils, which mediates an improvement in asthma control, an increase in FEV₁, a reduction in the number of exacerbations, and a decrease in the need for the OCS usage. Careful monitoring of long-term adverse events is necessary during treatment with benralizumab.

1. Alzaabi A., Idrees M., Behbehani N. Cross-sectional study on asthma insights and man-agement in the Gulf and Russia. Allergy Asthma Proc. 2018; 39 (6): 430–436. DOI: 10.2500/aap.2018.39.4180.

2. Hekking P.P.W., Wener R.R., Amelink M. et al. The prevalence of severe refractory asthma. J. Allergy Clin. Immunol. 2015; 135 (4): 896–902. DOI: 10.1016/j.jaci.2014.08.042.

3. Padilla-Galo A., Levy-Abitbol R.C., Olveira C. et al. Real-life experience with benralizumab during 6 months. BMC Pulm. Med. 2020; 20 (1): 184. DOI: 10.1186/s12890-020-01220-9.

4. Levy M.L. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015; 11 (1): 14–24. DOI: 10.1183/20734735.008914.

5. Pavord I.D. Eosinophilic phenotypes of airway disease. Ann. Am. Thorac. Soc. 2013; 10 (Suppl.): S143–149. DOI: 10.1513/AnnalsATS.201306-168AW.

6. Kolobovnikova Yu.V., Urazova O.I., Novitsky V.V. et al. Eosinophil: a modern concept of the kinetics, structure, and function. Gematologiya i transfuziologiya. 2012; 57 (1): 30–36. Available at: https://cyberleninka.ru/article/n/eozinofil-sovremennyy-vzglyad-na-kinetiku-strukturu-i-funktsiyu/viewer (in Russian).

7. Wenzel S.E. Inflammation, leukotrienes and the pathogenesis of the late asthmatic response. Clin. Exp. Allergy. 1999; 29 (1): 1–3. DOI: 10.1046/j.1365-2222.1999.00486.x.

8. Wen T., Rothenberg M.E. The regulatory function of eosinophils. Microbiol. Spectr. 2016; 4 (5). DOI: 10.1128/microbiolspec.MCHD-0020-2015.

9. Matuchi A., Maggi E., Vultaggio A. Eosinophils, the IL-5/IL-5Ra axis, and the biologic effects of benralizumab in severe asthma. Respir. Med. 2019; 160: 105819. DOI: 10.1016/j.rmed.2019.105819.

10. Hillas G., Fouka E., Papaioannou A.I. Antibodies targeting the interleukin- 5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev. Respir. Med. 2020; 14 (4): 353–365. DOI: 10.1080/17476348.2020.1718495.

11. Patel S.S., Casale T.B., Cardet J.C. Biological therapies for eosinophilic asthma. Expert Opin. Biol. Ther. 2018; 18 (7): 747–754. DOI: 10.1080/14712598.2018.1492540.

12. Bakakos A., Rovina N., Bakakos P. Treatment challenges in severe eosinophilic asthma: differential response to anti-IL-5 and anti- IL-5R therapy. Int. J. Mol. Sci. 2021; 22 (8): 3969. DOI: 10.3390/ijms22083969.

13. Hambly N., Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr. Opin. Pulm. Med. 2014; 20 (1): 87–94. DOI: 10.1097/MCP.0000000000000007.

14. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1.

15. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8.

16. Ghazi A., Trikha A., Calhoun W.J. Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert Opin. Biol. Ther. 2012; 12 (1): 113–118. DOI: 10.1517/14712598.2012.642359.

17. Pham T.H., Damera G., Newbold P., Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir. Med. 2016; 111: 21–29. DOI: 10.1016/j.rmed.2016.01.003.

18. Castro M., Wenzel S.E., Bleecker E.R. et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2014; 2 (11): 879–890. DOI: 10.1016/S2213-2600(14)70201-2.

19. Pelaia C., Busceti M.T., Vatrella A. et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm. Pharmacol. Ther. 2019; 58: 101830. DOI: 10.1016/j.pupt.2019.101830.

20. Renner A., Marth K., Patocka K. et al. Benralizumab rapidly improves asthma control in Austrian real-life severe eosinophilic asthmatics. Allergy. 2020; 75 (12): 3272–3275. DOI: 10.1111/all.14441.

21. Kavanagh J.E., Hearn A.P., Dhariwal J. et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021; 159 (2): 496–506. DOI: 10.1016/j.chest.2020.08.2083.

22. Nair P., Wenzel S., Rabe K.F. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 2017; 376 (25): 2448–2458. DOI: 10.1056/NEJMoa1703501.

23. Liu W., Ma X., Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis. Medicine (Baltimore). 2019; 98 (22): e15868. DOI: 10.1097/MD.0000000000015868.

24. Busse W.W., Bleecker E.R., FitzGerald J.M. et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir. Med. 2019; 7 (1): 46–59. DOI: 10.1016/S2213-2600(18)30406-5.

25. Bourdin A., Shaw D., Menzies-Gow A. et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J. Asthma. 2021; 58 (4): 514–522. DOI: 10.1080/02770903.2019.1705333.

26. Scioscia G., Carpagnano G.E., Quarato C.M.I. et al. Effectiveness of benralizumab in improving the quality of life of severe eosinophilic asthmatic patients: our real-life experience. Front. Pharmacol. 2021; 12: 631660. DOI: 10.3389/fphar.2021.631660.

27. Poznanski S.M., Mukherjee M., Zhao N. et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. Allergy. 2021; 76 (1): 375–379. DOI: 10.1111/all.14514.

28. Jackson D.J., Korn S., Mathur S.K. et al. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020; 43 (5): 409–425. DOI: 10.1007/s40264-020-00926-3.

29.